FUROSCIX (furosemide injection 80 mg/ 10 ml) by Scpharmaceuticals is 12. Approved for edema in pediatric patients weighing 43 kg, above, chronic kidney disease and 1 more indications. First approved in 2022.
Drug data last refreshed 13h ago · AI intelligence enriched 16h ago
FUROSCIX is a subcutaneous furosemide injection (80 mg/10 mL) that inhibits sodium and chloride reabsorption in the loop of Henle and proximal/distal tubules, producing diuresis comparable to intravenous administration. It is indicated for edema management in pediatric patients ≥43 kg and adults with chronic kidney disease, including nephrotic syndrome. The subcutaneous infusion formulation (30 mg over 1 hour followed by 12.5 mg/hour for 4 hours) offers an alternative to bolus IV dosing with similar efficacy and up to 8 hours of diuretic effect.
Early-stage peak lifecycle product with limited payer adoption (1,783 Part D claims in 2023) suggests brand-building and market education remain priorities for the commercial team.
12.1 Mechanism of Action Furosemide primarily inhibits the reabsorption of sodium and chloride in the proximal and distal tubules and in the loop of Henle. The high degree of diuresis is largely due to the unique site of action. The action on the distal tubule is independent of any inhibitory…
Worked on FUROSCIX at Scpharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Loop Diuretic
Upgrade to Pro to access patent cliff timelines and LOE dates and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moFUROSCIX represents a niche specialty pharmaceutical opportunity with modest current uptake (1,783 Part D claims, $9M spending in 2023) but significant market-building potential. Professionals joining this franchise would focus on payer education, patient access optimization, and overcoming infusion site tolerability barriers to drive adoption in chronic kidney disease and heart failure populations.